OncLive SOSS

Authors

Thomas Hutson, DO, PharmD, FACP, Baylor University Medical Center

Thomas Hutson, DO, PharmD, Texas Oncology–Baylor

Thomas J. Herzog, M.D., Professor of Obstetrics and Gynecology, Deputy Director, University of Cincinnati Cancer Institute

Latest:

Rethinking I-O in PROC: A Potential Answer in Two vs. One

Thomas J. Kipps, MD, PhD

Latest:

The Advent of the BTK inhibitor

Thomas J. Kipps, MD, PhD, UC San Diego Moores Cancer Center

Thomas J. Kipps, MD, UCSD

Thomas J. Lynch, Jr., MD

Latest:

Dr. Lynch on Targeting EGFR Mutation Subtypes in Lung Cancer

Thomas J. Lynch, MD, CEO, chairman, Massachusetts General Hospital Physicians Organization, discusses targeting EGFR mutation subtypes as a frontline treatment for lung cancer.

Thomas J. Lynch, MD

Latest:

Precision Medicine: A Promising Future for Treating Cancer

Thomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.

Thomas J. Polascik, MD

Latest:

Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate Cancer

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

Thomas J. Semrad, MD

Latest:

Dr. Semrad on SPIDER Program to Understand Resistance to Therapies

Thomas J. Semrad, MD, assistant professor, co-director, Phase I Program, UC Davis Health System, discusses the Serial Patient-Derived Xenografts to Understand Cancer Therapy Resistance (SPIDER) program at UC Davis Health System, aimed at understanding patient resistance to cancer therapies.

Thomas Karasic, MD

Latest:

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

Thomas Kipps, MD, PhD

Thomas LeBlanc, MD

Latest:

Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Thomas Lynch, Jr, MD

Latest:

Dr. Lynch on the Immuno-Oncology Network at Bristol-Myers Squibb

Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the Immuno-Oncology (IO) Network at Bristol-Myers Squibb.

Thomas M. Churilla, MD

Latest:

Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

Thomas Marron, MD, PhD

Latest:

Dr Marron on the Evolving Role of Tarlatamab in SCLC

Thomas Marron, MD, PhD, discusses how findings from the DeLLphi-303 trial are shaping the use of tarlatamab across treatment settings in small cell lung cancer.

Thomas Martin, MD, UCSF Helen Diller Family

Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

Presented by Dr. Thomas Martin, this IMROZ subgroup analysis demonstrated that adding isatuximab to standard VRd therapy improved progression-free survival and deepened responses in transplant-ineligible patients with newly diagnosed multiple myeloma and 1q21+ status, a high-risk cytogenetic subgroup.

Thomas Powles MBBS, MRCP, MD

Thomas Powles, MBBS, MRCP, MD, is a professor of genitourinary oncology and the director of the Barts Cancer Centre at St. Bartholomew’s Hospital in London, England.

Latest:

Dr Powles on the Role of the CREST Study in Future Clinical Trial Design in BCG-Naive NMIBC

Thomas Powles, MBBS, MRCP, MD, discusses how future clinical trials could leverage the CREST trial as a basis for BCG-naive NMIBC treatment development.

Thomas Powles, MD

Latest:

Integrating ctDNA-Based MRD Testing in MIBC

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.